RIPK3 and neoplasm: Together, these findings support our hypothesis that RIPK3 has anti-tumor properties and that lack of RIPK3 promotes the development of intestinal neoplasia through STAT3- and β-catenin-mediated transcription of angiogenic, mitogenic, tumorigenic and cell cycle regulators.